{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=4", "query": { "intervention": "acalabrutinib", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T10:25:23.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukaemia", "Small Lymphocytic Lymphoma", "Mantle-cell Lymphoma", "Large B-cell Lymphoma", "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" }, { "name": "Prednisone (or equivalent)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-01-30", "completion_date": "2029-06-11", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 12, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564038" }, { "nct_id": "NCT02454179", "title": "Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02454179" }, { "nct_id": "NCT05205252", "title": "A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Hematologic Malignancy", "Refractory Hematologic Malignancy" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Daratumumab (Intravenously)", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Daratumumab (Subcutaneously)", "type": "DRUG" }, { "name": "Hyaluronidase-Fihj", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone 20mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-12-22", "completion_date": "2023-07-05", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 3, "location_summary": "Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey", "locations": [ { "city": "Santa Fe", "state": "California" }, { "city": "Bolivar", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05205252" }, { "nct_id": "NCT04402138", "title": "Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-08-07", "completion_date": "2024-04-05", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 4, "location_summary": "Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04402138" }, { "nct_id": "NCT02362048", "title": "ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ACP-196", "type": "DRUG" }, { "name": "ACP-196 in combination with pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2015-05", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2019-10-01", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02362048" }, { "nct_id": "NCT03527147", "title": "Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NHL", "DLBCL", "Non-hodgkin's Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" }, { "name": "Hu5F9-G4", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "AZD5153", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 30, "start_date": "2018-06-19", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 10, "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03527147" }, { "nct_id": "NCT04783415", "title": "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Ublituximab", "type": "BIOLOGICAL" }, { "name": "Umbralisib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-03-26", "completion_date": "2026-07-21", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04783415" }, { "nct_id": "NCT02717611", "title": "A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "ACP-196 (acalabrutinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-03-08", "completion_date": "2026-06-06", "has_results": true, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 16, "location_summary": "Tucson, Arizona • Concord, California • La Jolla, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717611" }, { "nct_id": "NCT04502394", "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2021-02-23", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-08-04", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 4, "location_summary": "Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Goshen", "state": "Indiana" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04502394" }, { "nct_id": "NCT04898101", "title": "A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Microtracer [14C]ACP-196", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2016-03-03", "completion_date": "2016-04-13", "has_results": false, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-10-05T10:25:23.312Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04898101" } ] }